Clinical utility of cell-free DNA for the detection of ALK fusions and genomic mechanisms of ALK inhibitor resistance in non-small cell lung cancer

PURPOSE: Patients with advanced non-small cell lung cancer (NSCLC) whose tumors harbor anaplastic lymphoma kinase (ALK) gene fusions benefit from treatment with ALK inhibitors (ALKi). Analysis of cell-free circulating tumor DNA (cfDNA) may provide a non-invasive way to identify ALK fusions and actio...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: McCoach, Caroline E., Blakely, Collin M., Banks, Kimberly C., Levy, Benjamin, Chue, Ben M., Raymond, Victoria M., Le, Anh T., Lee, Christine E., Diaz, Joseph, Waqar, Saiama N., Purcell, William T., Aisner, Dara L., Davies, Kurtis D., Lanman, Richard B., Shaw, Alice T., Doebele, Robert C.
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6157019/
https://ncbi.nlm.nih.gov/pubmed/29599410
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-2588
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados